Circulomics Inc – Trademark Portfolio
Entity Type: 03
Circulomics Inc holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include NANOBIND, CIRCULOMICS, and SHORT READ ELIMINATOR. The owner is based in Baltimore, MD.
701 E. Pratt Street
Baltimore, MD 21202
Showing of trademarks Trademarks
Trademark Classifications
Circulomics Inc's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Circulomics Inc have?
Circulomics Inc has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does Circulomics Inc file in?
Circulomics Inc files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Circulomics Inc's most well-known trademarks?
Circulomics Inc's registered trademark portfolio includes well-known marks such as NANOBIND, CIRCULOMICS, and SHORT READ ELIMINATOR. These are among 3 currently registered trademarks in the portfolio.
What is Circulomics Inc's trademark registration success rate?
Circulomics Inc has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.